June 2017 DAIDS Council-Approved Concepts

Concepts represent early planning stages for program announcements, requests for applications, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to Opportunities & Announcements.

NB: Council approval does not guarantee that a concept will become an initiative.

Table of Contents

Targeted In Vivo Delivery of Gene Therapeutics for HIV Cure

For the published request for applications, see the April 20, 2018 Guide announcement, Targeted In Vivo Delivery of Gene Therapeutics for HIV Cure (R01 Clinical Trial Not Allowed).

Next Generation Biologics for Sustained HIV Remission

For the published request for applications, see the April 11, 2018 Guide announcement, Next-Generation Biologics for Sustained HIV Remission (R01 Clinical Trial Not Allowed).

NIH AIDS Reagent Program

Request for Proposals—proposed FY 2019 initiative

Contact: Kishan Patel

Objective: The objective of the NIH AIDS Reagent Program (ARP) is to facilitate HIV/AIDS research by providing access to standardized state-of-the-art reagents, technology, and other research resources to investigators around the world.

Description: This initiative will provide continued support for a contract to acquire state-of-the-art HIV/AIDS-related research and reference reagents; produce reagents, standardized panels, and protocols; and provide these reagents at minimal cost to qualified investigators throughout the world. Additionally, the ARP collects information about AIDS-related reagents and standards and disseminates this information to the research community, enhances technology transfer and publication of methods, and facilitates the availability of reagents through proactive communication with biotechnology and pharmaceutical companies.

HIV Drug Resistance: Genotype-Phenotype-Outcome Correlations

For the published request for applications, see the July 24, 2018 Guide announcement, HIV Drug Resistance: Genotype-Phenotype-Outcome Correlations (R01 Clinical Trial Not Allowed).  

NIAID Virology Quality Assurance (VQA) Program

For the published requests for proposals, see the May 2, 2018 solicitation, NIAID Virology Quality Assurance (VQA) Program.

Halting TB Transmission in HIV-Endemic Settings

For the published request for applications, see the July 3, 2018 Guide announcement, Halting TB Transmission in HIV-Endemic and Other High-Transmission Settings (R01, Clinical Trial Not Allowed).

Understanding Immunopathogenesis of Tuberculosis in HIV-1 Infected and Exposed Children

For the published request for applications, see the December 4, 2017 Guide announcement, Understanding Immunopathogenesis of Tuberculosis in HIV-1 Infected and Exposed Children (R01 Clinical Trial Not Allowed).

Harnessing Big Data To Halt HIV

For the published program announcement with special receipt, referral, and/or review considerations, see the April 20, 2018 Guide announcement, Harnessing Big Data to Halt HIV (R01 Clinical Trial Optional).

Imaging the Persistent HIV Reservoir

For the published program announcement, see the June 6, 2017 Guide announcement, Imaging the Persistent HIV Reservoir (R01).

Optimizing Phylodynamics To Target and Interrogate Clusters (OPTICS)

For the published program announcement, see the June 7, 2017 Guide announcement, Optimizing HIV Phylodynamics to Target and Interrogate Clusters (OPTICS) (R21).